Under the terms of the agreement, MitoProd will produce custom long RNA oligonucleotides for Sigma-Aldrich customers. The partnership further expands Sigma-Aldrich's comprehensive custom oligonucleotide service portfolio.
RNA molecules offer significant promise for a variety of applications in therapeutics and pharmaceutical development and production. MitoProd has developed a proprietary technology that enables the in vivo synthesis of ribonucleic acids. Based on baker yeast fermentation, MitoProd's technology enables the production of large homogeneous batches of ribonucleic acids without limitation on length or quantity.
"Sigma-Aldrich's established distribution network will greatly expand the market for our custom RNA products and services," said Guillaume Plane, CEO of MitoProd SA. "We are proud to collaborate with such a well-known life science company."
"This partnership further augments Sigma-Aldrich's portfolio of custom life science tools," said Khalil Arar, Business Development Director of Sigma-Aldrich Custom Products. "Harnessing MitoProd's technology, we can now offer customized long RNA synthesis capabilities to our life science customers worldwide."
Sigma-Aldrich offers a comprehensive collection of customized oligonucleotide services, from DNA oligos and probes to RNA and siRNA oligos and peptide synthesis.